Physician profile
Reena S Varade
NPI 1881039493
$3,543.69
in general payments reported to CMS, 2019-2025
22 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $51.33 · 2021: $587 · 2022: $342 · 2023: $291 · 2024: $908 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.57 |
| Education | $160.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $728.46 | 2020-2025 | Skyrizi |
| Pfizer INC. | $602.21 | 2019-2025 | |
| Janssen Biotech, INC. | $421.76 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $405.02 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $215.61 | 2024-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $191.41 | 2024-2025 | Zoryve |
| Ucb, INC. | $166.01 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $118.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.64 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $90.10 | 2021-2022 | |
| Organon LLC | $74.35 | 2025 | Vtama |
| Dermavant Sciences, INC. | $70.61 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $64.95 | 2022 | |
| Revance Therapeutics, INC. | $57.04 | 2024 | Daxxify |
| Lilly USA, LLC | $51.56 | 2023-2025 | Ebglyss, Taltz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $45.51 | 2019 | |
| Epi Health, LLC | $26.45 | 2020 | |
| Incyte Corporation | $25.58 | 2024 | Opzelura |
| Merck Sharp & Dohme LLC | $25.23 | 2019 | |
| Genzyme Corporation | $22.07 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.94 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.19 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Varade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.